MFC
Financials
Valuation Metrics
MFC's Market Cap is ₩196B. At end of 2025 it was ₩300B. Ranked #2285 of 2,410 in KR market (top 95%), #1520 of 1,631 on KOSDAQ (top 93%), #225 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 19.63B KRW | KR#2,285/2,410 Sec#225/231 |
| Revenue | 18.70B KRW | KR#2,151/2,410 Sec#159/231 |
| Net Income | -609.1M KRW | KR—/2,410 Sec—/231 |
| Total Assets | 33.94B KRW | KR#2,305/2,410 Sec#215/231 |
| Net Assets | 29.18B KRW | KR#2,178/2,410 Sec#197/231 |
| Employees | 70 | KR#1,869/2,410 Sec#161/231 |
| Value | ||
| P/B | 0.67x | KR#1,149/2,410 Sec#64/231 |
| P/S | 1.05x | KR#1,469/2,410 Sec#84/231 |
| Profitability | ||
| ROE | -2.09% | KR#1,693/2,410 Sec#118/231 |
| ROA | -1.79% | KR#1,734/2,410 Sec#122/231 |
| Op. Margin | -3.00% | KR#1,772/2,410 Sec#120/231 |
| Revenue Growth | 0.95% | KR#1,459/2,410 Sec#145/231 |
| Financial Health | ||
| Debt Ratio | 16.34% | KR#280/2,410 Sec#42/231 |
| Total Debt | 2.99B KRW | KR#1,863/2,410 Sec#179/231 |
| Cash | 5.15B KRW | KR#1,988/2,410 Sec#185/231 |
| Current Ratio | 3.88x | KR#403/2,410 Sec#64/231 |
| Performance | ||
| 1Y Return | -40.18% | KR#1,750/2,410 Sec#145/231 |
| 1M Return | -12.45% | KR#1,235/2,410 Sec#126/231 |
| From 52W High | -49.56% | KR#1,161/2,410 Sec#92/231 |
| 1Y MDD | -43.65% | KR#698/2,410 Sec#49/231 |
| Trading | ||
| Volume | 3,239 shares | KR#2,249/2,410 Sec#225/231 |
| Trading Value | 7.3M KRW | KR#2,319/2,410 Sec#229/231 |
| Foreign Own. | 1.14% | KR#1,966/2,410 Sec#194/231 |
| Per Share | ||
| EPS | -71 KRW | KR—/2,410 Sec—/231 |
| BPS | 3,396 KRW | KR#1,783/2,410 Sec#133/231 |
Company Info
MFC, established in 2008, is a specialized company in Active Pharmaceutical Ingredient (API) and material development and manufacturing, listed on the KOSDAQ market as a technology growth company in 2024. Utilizing organic synthesis, mass production, and new crystallization technologies, MFC develops and mass produces APIs, Key Starting Materials (KSM), and Pharmaceutical Intermediates (PI). The company produces and sells APIs for various therapeutic areas, including cardiovascular, digestive, and anti-inflammatory and analgesic treatments. MFC is pursuing market preemption by securing intellectual property rights for new crystal forms and salts in the improved new drug raw materials sector. The company is headquartered in Hwaseong-si, Gyeonggi-do.